Agree in part, but disagree on the dividend. Dividend can be an important part of total return for mature companies. In my opinion, GILD is still a GROWTH company and I would rather see the money that will be paid out in dividends used for growth and acquisition. GILD's focus should be on strategic acquisitions-not sure about VRTX-but I think ICPT or ACAD (with potential $4B drug) fit nicely. ACAD seems slightly undervalued while ICPT seems slightly overvalued, but a purchase of either at a reasonable price would make good sense and I think the stock would move accordingly.
Only those without a clue (and there are many) would sell on this news. I'm sure CNBC (clueless) and Bloomberg (anti-Gilead) will pump this story. But, in reality the Merck results just crystalizes the fact that Gilead is #1 in HCV and will stay that way for a long time.
Short it here. You sound like you know a lot about it. LOL Any cardiologist worth his weight would have already seen this problem coming. The reality is Abbvie has already given up on HCV market. HEP C Rx will be repriced (up!) next January. If you can't wait that long maybe you can at least hold until GILD reports great earnings in a month or so. Remember the co. has a huge buyback program in place any large weakness like this morning means more shares for the GILD treasury.
That's the funniest post all week. ESRX is the only PBM or major carrier forcing their participants to use "an inferior drug" We have to call it what it is. I think ESRX is embarrassed at this point that everyone else has chosen Gilead and that's why they have to vice their "concerns" in public. ABBV is getting hurt badly by their decision to discount also-though they had to because of their inferior product.
Wrong! Volume is way below average. This is a retail sell off based on CNBC's moronic ESRX shill. Anyone who sells here gets what they deserve.
Most don't even belong in individual stocks because they can't handle volatility.
They think stocks just go up and up and never look back. They're naïve. Buy stocks you believe in and stick with it. That's the only way you will beat the daylights out of the day traders who in the end will be the BIG losers
I hear you. The CS analyst with the downgrade on Friday used to work for Steve Cohen at SAC Capital. Enough said.
4 million U.S. and 200 million world-wide. The problem is growing not shrinking. Remember GILD has paid for the $11B cost of it's HCV program in one year. The math is not exact, but close enough. In 5 years GILD will be #1 in HIV, HCV, HBV and NASH. Mark my words!
Why next week how about a year...2 yrs....3yrs. You're a trader, eh? How much do you make a year trading?
I'd really like to know? I have to check but I think I used to run into you on the BX board. Your constant bad-mouthing there led to all-time highs. Same coming here.
I'll take that one. Because according to NIH about 80% of those exposed to the virus develop a chronic infection. Approximately 150-200 million people are infected worldwide. Go to the NIH website if you want education.